Choice of Taxane and Outcomes in the KEYNOTE-407 Study of Pembrolizumab Plus Chemotherapy for Metastatic Squamous NSCLC

Halmos, B.Luft, A.Majem, M.Hui, R.Corre, R.Gumus, M.Laktionov, K.2024-06-122024-06-1220181556-08641556-1380https://doi.org/10.1016/j.jtho.2018.08.400https://hdl.handle.net/20.500.14551/21765[Abstract Not Available]en10.1016/j.jtho.2018.08.400info:eu-repo/semantics/openAccessImmunotherapyPD-1ChemotherapyChoice of Taxane and Outcomes in the KEYNOTE-407 Study of Pembrolizumab Plus Chemotherapy for Metastatic Squamous NSCLCConference Object1310S391S391Q1WOS:000454014501037